IJPSR (2024), Volume 15, Issue 1 (Review Article)

INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH

Received on 19 May 2023; received in revised form, 02 August 2023; accepted, 21 November 2023; published 01 January 2024

# *IN-VIVO* AND *EX-VIVO* METHODS: ADVANCING THE FRONTIERS OF OCULAR PHARMACOLOGICAL RESEARCH

Shubhangi Shelar [1], Nigar Kadar Mujawar [2] and Snehal S. Chakorkar [* 1]

Department of Pharmacology [1], Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune - 411018, Maharashtra, India.
Department of Pharmaceutics [2], Womens College of Pharmacy, Peth Vadgaon - 416112, Maharashtra, India.

**Keywords:**

*In-vivo* methods, *Ex-vivo* methods, Ocular study, Pharmacological research

**Correspondence to Author:**
**Snehal S. Chakorkar**

Assistant Professor,
Department of Pharmacology,
Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune - 411018, Maharashtra, India.

**E-mail:** snehalchakorkar@gmail.com

**ABSTRACT:** Pharmacological research is a complex and challenging field that seeks to understand the effects of drugs on living organisms. *In-vivo* and *ex-vivo* methods are two of the most essential tools used in pharmacological research, each with its own advantages and disadvantages. *In-vivo* methods involve testing drugs in living organisms, typically animals. This type of research can provide valuable information about the effects of drugs on the entire organism, including its metabolism, distribution, and elimination. However, *in-vivo* research can be expensive, time-consuming, and ethically challenging. *Ex-vivo* methods involve testing drugs on isolated tissues or cells. This type of research can provide more detailed information about the mechanisms of action of drugs, but it needs to consider the drug's effects on the entire organism. The use of *in-vivo* and *Ex-vivo* methods together can provide a complete understanding of the effects of drugs. *In-vivo* methods can be used to identify potential new drugs, while *ex-vivo* methods can be used to study the mechanisms of action of drugs and to optimize their dosage and delivery. The use of *in-vivo* and *ex-vivo* methods has advanced the frontiers of pharmacological research in several ways. For example, *In-vivo* methods, such as optical coherence tomography and fund us imaging, allow for non-invasive imaging of the living eye. *Ex-vivo* methods, including histology and electron microscopy, provide high-resolution images of ocular tissues in a controlled laboratory setting. The use of *in-vivo* and *ex-vivo* methods is likely to advance the frontiers of pharmacological research in the years to come.

**INTRODUCTION:** The study of the eye is crucial in understanding and treating various ocular diseases. *In-vivo* and *ex-vivo* studies are two methods used to investigate the structure and function of the eye [1]. *In-vivo* studies involve analyzing the eye while it is still in its natural state within the body. *Ex-vivo* studies involve analyzing the eye after removing it from the body [2].

QUICK RESPONSE CODE

DOI: 10.13040/IJPSR.0975-8232.15(1).78-86

This article can be accessed online on www.ijpsr.com

DOI link: https://doi.org/10.13040/IJPSR.0975-8232.15(1).78-86

Correlating the results of *in-vivo* and *Ex-vivo* studies can provide a more comprehensive understanding of ocular diseases. Animal models are essential biomedical research tools that help bridge the gap between basic research and clinical trials [3].

*In-vivo* and *ex-vivo* animal models are commonly used to study various human diseases and conditions. *In-vivo* models are living animals used to study the effects of interventions or diseases. In contrast, *ex-vivo* models involve animal tissues or organs removed from the body and studied outside their natural environment [4]. This article will explore examples of *ex-vivo* and *in-vivo* animal model correlation.

*In-vivo* animal models involve studying a process or condition within a living organism. This can include studying the effects of a drug on an animal's behavior or the progression of a disease in an animal over time. *In-vivo* models investigate the biological processes that occur within the whole organism. They are often used to test the safety and efficacy of drugs before they are tested in humans [5]. *Ex-vivo* animal models, on the other hand, involve studying biological processes outside of a living organism, typically in isolated tissues or cells. *Ex-vivo* models are often used to investigate specific cellular or molecular mechanisms and can be more controlled and precise than *In-vivo* models [6].

The correlation between *Ex-vivo* and *In-vivo* animal models is essential because the results obtained from these models can complement each other and provide a more comprehensive understanding of the biological processes being studied [7]. For example, *ex-vivo* models can investigate specific molecular mechanisms underlying disease. In contrast, *in-vivo* models can be used to study the overall progression of the disease within a living organism. Combining these two approaches can provide a complete understanding of the disease and its underlying mechanisms, ultimately leading to better treatments and therapies.

**Basics Involved in Ocular *In-vivo* Studies:** *In-vivo* studies use non-invasive imaging techniques to examine the eye. The most common animal models used in ocular *in-vivo* studies are rabbits, rats, and mice. These animals have similar eye anatomy to humans and can be bred and maintained in a controlled environment [8]. Optical coherence tomography (OCT) is a commonly used technique that uses light waves to capture images of the eye's internal structures. OCT can provide detailed information on the retina, optic nerve, and other ocular structures [9]. Other *in-vivo* techniques include fundus photography, which captures retina images, and electroretinography (ERG), which measures the retina's electrical response to light.

**Basics Involved in Ocular *Ex-vivo* Studies:** *Ex-vivo* ocular studies are a type of research that involves the study of living tissue that has been removed from the body. This type of study can be used to investigate the effects of different treatments or conditions on the eye without the need to perform surgery on a living animal. This involves the removal of the eye, which allows for a more detailed analysis of its structures [10]. One standard method is to remove the eye from the body and place it in a special chamber that maintains the temperature and humidity of the eye. The eye can then be studied under a microscope or exposed to different treatments or conditions. Histological analysis is commonly used to examine the cellular and tissue-level changes in ocular diseases[11]. This involves slicing the eye into thin sections and staining the tissue to highlight specific structures. Electron microscopy is another technique used in *Ex-vivo* studies to visualize the ultra structure of ocular tissues [12]. Another method of performing an *Ex-vivo* ocular study is to use a tissue culture. In this type of study, cells from the eye are grown in a laboratory dish. The cells can then be studied under a microscope or exposed to different treatments or conditions.

**Correlating *In-vivo* and *Ex-vivo* Studies:** Correlating the results of *In-vivo* and *Ex-vivo* studies can provide a more comprehensive understanding of ocular diseases. For example, *In-vivo* imaging techniques can detect changes in the eye's structure and function over time [13]. *Ex-vivo* studies can confirm these changes and provide a more detailed analysis of the cellular and tissue-level changes.

In a study on glaucoma, *In-vivo* OCT imaging was used to identify changes in the optic nerve head over time [14]. *Ex-vivo* histological analysis was then used to confirm these changes and provide a more detailed understanding of the cellular and tissue-level changes that occur in glaucoma.

Correlation between *ex-vivo* and *in-vivo* models *Ex-vivo* models are advantageous as they allow for a controlled environment where specific cells or tissues can be manipulated without interfering with other bodily functions [2]. The isolated tissues or cells can be studied in a way impossible in living animals. *Ex-vivo* models also provide a faster and cheaper alternative to *in-vivo* models, allowing for preliminary testing before *in-vivo* studies. However, *ex-vivo* models only partially reflect the complexity of *in-vivo* models, as they lack the influence of the immune system, surrounding

tissues, and overall physiological processes. *In-vivo* models are advantageous as they provide a more realistic representation of the effects of interventions in living organisms [15-16]. *In-vivo* models evaluate the safety, efficacy, and toxicity of new drugs or interventions. *In-vivo* models also evaluate the pharmacokinetics and pharmacodynamics of drugs and their metabolites. The correlation between *ex-vivo* and *in-vivo* models is essential to ensure that results obtained from animal studies are reliable and translate to humans [17].

It is necessary to use both models to evaluate the pharmacokinetics, pharmacodynamics, and toxicity of drugs and their metabolites. It is also essential to ensure that the *Ex-vivo* models used are relevant to the *In-vivo* models used.

**Common Examples of *Ex-vivo* and *In-vivo* Model Correlation:** *Ex-vivo* and *In-vivo* model correlation has been studied in various fields of research.

**Some Ocular *Ex-vivo* Models are:**

**Corneal Drug Delivery:** *Ex-vivo* corneal drug delivery models are used to study the transport of drugs across the cornea. This information can be used to design more effective drug delivery systems with fewer side effects [18].

**Retinal Degeneration:** *Ex-vivo* retinal degeneration models are used to study the progression of retinal diseases. This information can be used to develop new treatments for these diseases [19].

**Diabetic Retinopathy:** *Ex-vivo* diabetic retinopathy models are used to study the effects of diabetes on the retina. This information can be used to develop new treatments for diabetic retinopathy [20].

**Some Ocular *In-vivo* Models are:**

**Ocular Drug Delivery:** *In-vivo* ocular drug delivery models are used to test the efficacy and safety of new drug delivery systems. This information can bring new drugs to market more quickly and efficiently [21].

**Retinal Imaging:** *In-vivo* retinal imaging diagnoses and monitors retinal diseases. This information can be used to provide early intervention and improve patient outcomes.

**Glaucoma:** *In-vivo* glaucoma models are used to study the progression of glaucoma. This information can be used to develop new treatments for this disease [22].

*Ex-vivo* models have been used to study drug resistance, efficacy, and the mechanisms of action of drugs used in ocular disease [23]. *In-vivo* models have evaluated new drugs' safety, efficacy, and toxicity. A study published in the journal "Ophthalmology" 2004 investigated the *In-vitro* and *Ex-vivo* ocular drug delivery of loteprednol etabonate [24].

The study found that there was a good correlation between the *in-vitro* and *Ex-vivo* drug release profiles of loteprednol etabonate. This means that loteprednol etabonate's in vitro release profiles can be used to predict its *In-vivo* release profile. This significant correlation allows for the development more effective and efficient ophthalmic formulations of loteprednol etabonate. It also provides a more accurate prediction of the therapeutic effects of loteprednol etabonate. Here are some additional details about the *In-vitro* and *Ex-vivo* studies conducted on loteprednol etabonate: *In-vitro* drug release testing was conducted using Franz diffusion cells. *Ex-vivo* transcorneal drug permeation studies were conducted using rabbit corneas. The results of these studies showed that there was a good correlation between the *In-vitro* and *Ex-vivo* drug release profiles of loteprednol etabonate. This means that loteprednol etabonate's *in-vitro* release profiles can be used to predict its *In-vivo* release profile. This significant correlation allows for the development more effective and efficient ophthalmic formulations of loteprednol etabonate. It also provides a more accurate prediction of the therapeutic effects of loteprednol etabonate.

**Give the History of *In-vivo* and *Ex-vivo* Ocular Study Correlation:** The study of the eye has a long and fascinating history, dating back to ancient times when the Greeks and Romans made observations about the structure and function of the eye [25]. However, the correlation between *In-vivo* and *Ex-vivo* ocular studies is more recent. The

correlation between *in-vivo* and *ex-vivo* ocular studies became an important area of research in the 20th century with the development of new technologies allowed for more detailed examination of the eye. One critical development was the use of electron microscopy, which enabled researchers to examine the cellular and subcellular structure of the eye in much greater detail than was possible with traditional light microscopy [14, 26]. This led to a better understanding of the cellular processes involved in ocular disease and the development of new treatments. Another important development was the use of animal models to study ocular disease. Using animal models, researchers could conduct In-vivo studies that closely mimicked the human eye, allowing for a better understanding of disease processes and new treatments. *Ex-vivo* studies also played a vital role in the development of new treatments for ocular disease. By examining tissue samples, researchers were able to identify the cellular processes involved in disease and develop targeted treatments that could be administered directly to the affected area. Today, the correlation between *In-vivo* and *Ex-vivo* ocular studies continues to be an important area of research as new technologies and treatment options are developed to address the many complex diseases and conditions that affect the eye [2, 27].

**Advantages of *Ex-vivo* and *In-vivo* Animal Model Correlation:** Each model type has advantages and limitations, and correlating data can provide a more comprehensive understanding of the disease or treatment under investigation[28,29,30].

**TABLE 1: ADVANTAGES OF *EX-VIVO* AND *IN-VIVO* ANIMAL MODEL CORRELATION**

| Advantages of *Ex-vivo* models | Advantages of *In-vivo* models |
|---|---|
| Greater control over experimental conditions, such as the concentration of drugs or growth factors administered to the cells or tissues | The ability to study the complex interactions between different organs and systems in a living organism can provide a more realistic representation of the disease or treatment |
| The ability to study specific cells or tissues in isolation, without interference from other biological factors | The potential to observe the long-term effects of treatments, such as the development of resistance or side effects |
| It reduced ethical concerns and costs associated with animal use | The ability to evaluate the safety and efficacy of treatments more comprehensively |
| *Ex-vivo* methods are less expensive and time-consuming than *In-vivo* methods | *In-vivo* methods are more realistic than *Ex-vivo* methods because they allow researchers to study the effects of drugs in the context of a living organism |
| *Ex-vivo* methods are also easier to control than *In-vivo* methods, which makes it easier to interpret the results of experiments | *In-vivo* methods can also be used to study the effects of drugs on the entire organism, including the immune, cardiovascular, and central nervous systems |
| *Ex-vivo* methods are also less ethically problematic than In-vivo methods because they do not involve using living animals or humans | *In-vivo* methods are also more sensitive than *Ex-vivo* methods, which means they can detect more minor changes in the effects of drugs |

By correlating data from *Ex-vivo* and *In-vivo* models, researchers can better understand the disease or treatment being studied. For example, they may observe a specific drug having a beneficial effect on cells in an *Ex-vivo* model but also see that the same drug has a toxic impact on specific organs in an *In-vivo* model. Such findings can guide the development of more effective and safe treatments.

**Disadvantages of *Ex-vivo* and *In-vivo* animal Model Correlation:** Some individual disadvantages [31, 32, 16].

**TABLE 2: DISADVANTAGES OF *EX-VIVO* AND *IN-VIVO* ANIMAL MODEL CORRELATION**

| Disadvantages of *Ex-vivo* models | Disadvantages of *In-vivo* models |
|---|---|
| *Ex-vivo* methods are less realistic than *In-vivo* methods because they need to allow researchers to study the effects of drugs in the context of a living organism | *In-vivo* methods are more expensive and time-consuming than *Ex-vivo* methods |
| *Ex-vivo* methods can also be less sensitive than *In-vivo*methods, which means that they may not be able to detect more minor changes in the effects of drugs | *In-vivo* methods can also be more challenging to control, making it difficult to interpret the results of experiments |
| *Ex-vivo* methods can also be fewer representatives of the effects of drugs in humans than *In-vivo* methods because they are typically conducted on animal tissues | *In-vivo* methods can also be more ethically problematic than *Ex-vivo* methods because they involve the use of living animals or humans |

*Ex-vivo* and *In-vivo* animal models are widely used in scientific research to study diseases and test new treatments. However, there are some disadvantages to correlating the results obtained from these two types of models [21, 16, 8]:

**Differences in the Environment:** *Ex-vivo* studies are conducted *in-vitro*, outside a living organism, while *In-vivo* studies are completed within a living organism. This difference in the environment can lead to differences in results and limits the direct correlation between the two models [33].

**Differences in Biological Complexity:** *Ex-vivo* models typically involve isolated cells or tissues, while *In-vivo* models involve complex biological systems with multiple interacting components. Therefore, it can be difficult to generalize findings from an *Ex-vivo* model to an *In-vivo* model [4].

**Ethical Concerns:** Animal models are often used in *In-vivo* studies, and there are ethical concerns about the use of animals in scientific research. Using *Ex-vivo* models can reduce the need for animal models, but it may only be possible to partially replace them in some research[34].

**Cost and Feasibility:** *In-vivo* studies can be more expensive and time-consuming than *Ex-vivo* studies and may require specialized equipment and facilities. Therefore, it may not be feasible to conduct both types of studies for every research question [35].

**Limited Applicability to Humans:** Animal models may only sometimes accurately represent human biology or disease, which can limit the relevance of findings from animal models to human health. This can also affect the correlation between *Ex-vivo* and *In-vivo* models [20]. While *Ex-vivo* and *In-vivo* models are valuable tools in scientific research, their differences and limitations can affect the correlation between their results. Therefore, researchers should carefully consider the advantages and disadvantages of each model when designing their studies.

**Give Brief Information on Current Ocular Study *Ex-vivo* Models:** One type of *Ex-vivo* model is the corneal model, which is often used to study the transport of drugs across the cornea. In this model, a cornea is excised from an animal or human eye and mounted in a chamber to be perfused with a solution containing the drug of interest. The amount of drug that penetrates the cornea can then be measured and used to determine its effectiveness [36].

Another type of *Ex-vivo* model is the retinal explant model, which involves the removal of the retina from an animal or human eye and its placement in a culture dish [37]. This model is useful for studying retinal function and the effects of drugs or other treatments on the retina.

Finally, lens explant models can be used to study the formation and function of the lens. In these models, lenses are removed from animal or human eyes and cultured *in-vitro*, allowing researchers to learn the development and function of the lens in a controlled environment.

Overall, *Ex-vivo* models provide a valuable tool for ocular research, allowing researchers to study the structure and function of ocular tissues and test the efficacy of potential treatments in a controlled laboratory setting.

**Give Brief Information on Current Ocular Study *In-vivo* Models:** *In-vivo* models are studies conducted on living organisms, such as animals, to understand various biological processes and diseases. In the context of ocular research, *In-vivo* models are used to study various eye diseases' physiology, pathogenesis, and treatment.

Currently, there are several *In-vivo* models being used in ocular research. One such model is the mouse model, widely used for studying retinal diseases such as age-related macular degeneration, diabetic retinopathy, and retinal detachment. Other *In-vivo* models include the rat, rabbit, and zebrafish models, each with unique advantages for specific types of research [19, 20].

*In-vivo* models can be used to evaluate the efficacy and safety of various ocular drugs and therapeutic interventions. They can also be used to study the underlying mechanisms of diseases and to test new treatments for ocular disorders. In addition to these models, recent advancements in stem cell research have led to the development of new *In-vivo* models, such as humanized mouse models, that can be used to study human eye diseases and test potential

therapies. Overall, *In-vivo* models are essential tools in ocular research, and they continue to play a critical role in advancing our understanding of eye diseases and developing new treatments.

**Ocular Model:** Ocular drug delivery is challenging due to the eye's unique anatomical and physiological barriers. Various animal models are used to evaluate the efficacy and safety of ocular formulations before clinical trials. This review article will discuss *In-vivo* and *Ex-vivo* animal models used to develop ocular formulations.

***In-vivo* Animal Models:** *In-vivo* animal models involve the administration of the formulation directly into the eye of live animals. These models provide a reliable and practical way to evaluate the safety and efficacy of ocular formulations. The commonly used *In-vivo* animal models are rabbits, rats, mice, and guinea pigs.

**TABLE 3: VARIOUS ANIMAL MODELS USED FOR *IN-VIVO* STUDY**

| ***In-vivo* animal models** | **Description about model** |
|---|---|
| Rabbit Model:  | The rabbit model is the most commonly used *In-vivo* animal model for ocular formulations. The rabbit eye is similar to the human eye, making it an ideal model for evaluating the ocular drug delivery system. The rabbit model is used to study corneal permeability, ocular irritation, pharmacokinetics, and toxicity of ocular formulations. The rabbit model is preferred due to its large eye size, which facilitates easy formulation administration, and its similarity to the human eye[38] |
| Rat Model:  | The rat model is used to evaluate the pharmacokinetics of ocular formulations due to the availability of various rat-specific ocular tools and techniques. The rat eye is smaller than the rabbit eye, but it is still helpful for studying ocular drug delivery. The rat model evaluates the formulations' ocular irritation and corneal permeability [39] |
| Mice Model:  | The mouse model is used to evaluate the efficacy of ocular formulations due to the availability of various genetic tools and techniques. The mouse model is used to study corneal wound healing, inflammation, and neovascularization[40] |
| Guinea Pig Model:  | The guinea pig model is used to evaluate the ocular toxicity of formulations. The guinea pig model is preferred for ocular toxicity studies due to the similarity between the guinea pig and human ocular surface epithelial cells[41] |

***Ex-vivo* Animal Models:** *Ex-vivo* animal models involve animal eyes or corneas removed from the animal and placed in culture media. These models provide a cost-effective and ethical alternative to *In-vivo* models. The commonly used *Ex-vivo* animal models are bovine, porcine, and rabbit corneas.

**TABLE 4: VARIOUS ANIMAL MODELS USED FOR *EX-VIVO* STUDY**

| ***Ex-vivo* animal models** | **Description about model** |
|---|---|
| Bovine Cornea Model: | The bovine cornea model is used to evaluate the permeability of formulations due to the similarity between bovine and human corneal stroma[42] |
| Porcine Cornea Model: | The porcine cornea model is used to evaluate formulations' drug absorption and distribution due to the similarity between porcine and human corneal epithelium[43] |
| Rabbit Cornea Model: | The rabbit cornea model evaluates formulations' drug permeability and toxicity due to the similarity between rabbit and human corneal endothelium[44] |

**Give the Current status of *In-vivo* and *Ex-vivo* Ocular Evaluation:** *In-vivo* and *Ex-vivo* ocular evaluations are ongoing areas of research and development in the field of ophthalmology. *In-vivo* evaluation refers to assessing the eye while still within the living organism. In contrast, *Ex-vivo* evaluation involves analyzing the eye after it has been removed from the body.

*In-vivo* evaluation techniques include clinical assessments, such as visual acuity testing, ophthalmoscopy, and tonometry, which ophthalmologists routinely perform to diagnose and monitor various eye conditions. More advanced *In-vivo* techniques, such as optical coherence tomography (OCT), confocal microscopy, and adaptive optics, allow for high-resolution imaging of the eye's structures and can provide detailed information about ocular diseases and their progression [14, 42].

*Ex-vivo* evaluation involves the analysis of ocular tissues and cells that have been removed from the body, typically during surgical procedures. This allows for a detailed examination of the cellular and molecular components of the eye, as well as the development and testing of new diagnostic and therapeutic approaches. *Ex-vivo* techniques include histological analysis, immunohistochemistry, gene expression analysis, and proteomics.

Overall, both *In-vivo* and *Ex-vivo* ocular evaluation techniques constantly evolve and improve, enabling ophthalmologists and researchers to understand ocular diseases better and develop new treatments and therapies.

**RESULT AND DISCUSSION:** The review article discusses using *In-vivo* and *Ex-vivo* methods in pharmacological research. *In-vivo* methods involve testing drugs and other treatments in living animals, while *Ex-vivo* methods involve testing them in cells or tissues removed from the body. It focuses on the advantages and disadvantages of both *In-vivo* and *Ex-vivo* methods. *In-vivo* methods are more realistic than *Ex-vivo* but are more expensive and time-consuming. *Ex-vivo* methods are less realistic than *In-vivo* methods but are less costly and time-consuming.

The review article also discusses the ethical considerations of using animals in research. The authors argue that the use of animals in research is justified when it is done humanely and is likely to lead to the development of new treatments that will benefit human health. The review article concludes by discussing the future of pharmacological research. The authors argue that using *In-vivo* and *Ex-vivo* methods in combination with technological advances will lead to the developing of new and more effective treatments for a wide range of diseases. Here are some additional thoughts on the use of *In-vivo* and *Ex-vivo* methods in pharmacological research:

*In-vivo* methods are more realistic than *Ex-vivo* because they allow researchers to study the effects of drugs and other treatments in the context of the whole organism. This is important because the body is a complex system, and the effects of a drug or treatment can be influenced by a number of factors, including the age, sex, and health of the individual.

*Ex-vivo* methods are less realistic than *In-vivo* methods but are also less expensive and time-consuming. This makes them a valuable tool for screening potential drugs and treatments. *Ex-vivo* methods can also be used to study drugs' mechanisms of action and optimize their dosage.

The use of animals in research is a complex issue with ethical considerations. The authors of the review article argue that the use of animals in research is justified when it is done humanely and is likely to lead to the development of new treatments that will benefit human health.

The use of *In-vivo* and *Ex-vivo* methods, combined with technological advances, will lead to the development of new and more effective treatments for a wide range of diseases.

The review article concludes that *In-vivo* and *Ex-vivo* methods can be used together to improve the efficiency and effectiveness of pharmacological research. *In-vivo* methods can identify potential drugs and treatments, while *Ex-vivo* methods can be used to study their mechanism of action and optimize their dosage.

**CONCLUSION:** In conclusion, *Ex-vivo* and *In-vivo* animal models have been used extensively in biomedical research to study various diseases and conditions. Using both models, researchers can better understand the molecular mechanisms underlying these diseases and identify potential therapeutic targets. The examples discussed in this article demonstrate the importance of using both *In-vivo* and *Ex-vivo* models in biomedical research and the potential for correlation.

*In-vivo* and *Ex-vivo* animal models provide a reliable and practical way to evaluate the safety and efficacy of ocular formulations. The choice of animal model depends on the specific research question and the type of ocular formulation being evaluated. The selection of the appropriate animal model is critical for the development of safe and effective ocular formulations.

**ACKNOWLEDGEMENT:** We would like to acknowledge and express our obligations to our colleges Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri and Womens College of Pharmacy, PethVadgaon for providing necessary help.

**CONFLICT OF INTEREST:** The authors declare no conflict of interest, financial or otherwise.

## REFERENCES:

1. Stockinger P, Berlin A and Kampik D: segment. 2022; 118(Suppl 2):153-159. doi:10.1007/s00347-021-01439-9. Correlation
2. Moleiro AF, Conceição G, Leite-Moreira AF and Rocha-Sousa A: A Critical Analysis of the Available *in-vitro* and *Ex-vivo* Methods to Study Retinal Angiogenesis. J Ophthalmol 2017; 2017. doi:10.1155/2017/3034953
3. Mukherjee P, Roy S, Ghosh D and Nandi SK: Role of animal models in biomedical research: a review. Lab Anim Res 2022; 38(1):1-17. doi:10.1186/s42826-022-00128-1
4. Bellido T and Delgado-Calle J: *Ex-vivo* Organ Cultures as Models to Study Bone Biology. JBMR Plus 2020; 4(3): 1-10. doi:10.1002/jbm4.10345
5. Arora T, Mehta A and Joshi V: Substitute of animals in drug research: An approach towards fulfilling 4R′s. Indian J Pharm Sci 2011; 73(1): 1-6. doi:10.4103/0250-474x.89750
6. Xu Y, Shrestha N, Préat V and Beloqui A: An overview of *in-vitro*, *ex-vivo*, and *in-vivo* models for studying the transport of drugs across intestinal barriers. Adv Drug Deliv Rev 2021; 175: 113795. doi:10.1016/j.addr.2021.05.005
7. Swearengen JR: Choosing the right animal model for infectious disease research. Anim Model Exp Med 2018; 1(2): 100-108. doi:10.1002/ame2.12020
8. Olivares AM, Althoff K and Chen GF: Animal Models of Diabetic Retinopathy. Curr Diab Rep 2017; 17(10). doi:10.1007/s11892-017-0913-0
9. Fujimoto JG, Pitris C, Boppart SA and Brezinski ME: Optical coherence tomography: An emerging technology for biomedical imaging and optical biopsy. Neoplasia 2000; 2(1-2):9-25. doi:10.1038/sj.neo.7900071
10. Rousou C, Hoogenboom P, van Overdam KA, Storm G, Dorrestijn J and Mastrobattista E: A technical protocol for an experimental ex vivo model using arterially perfused porcine eyes. Exp Eye Res 2019; 181(December 2018): 171-177. doi:10.1016/j.exer.2019.02.003
11. Gurcan MN, Boucheron LE, Can A, Madabhushi A, Rajpoot NM and Yener B: Histopathological Image Analysis: A Review. IEEE Rev Biomed Eng 2009; 2: 147-171. doi:10.1109/RBME.2009.2034865
12. Frankl A, Mari M and Reggiori F: Electron microscopy for ultrastructural analysis and protein localization in *Saccharomyces cerevisiae*. Microb Cell 2015; 2(11): 412-428. doi:10.15698/mic2015.11.237
13. Hosseinaee Z, Pellegrino N and Abbasi N: *In-vivo*, functional and structural retinal imaging using multiwavelength photoacoustic remote sensing microscopy. Sci Rep 2022; (0123456789): 1-10. doi:10.1038/s41598-022-08508-2
14. Geevarghese A, Wollstein G, Ishikawa H and Schuman JS: Optical Coherence Tomography and Glaucoma. Published online 2022:693-726. doi:10.1146/annurev-vision-100419-111350.Optical
15. Hammel JH, Cook SR, Belanger MC, Munson JM and Pompano RR: HHS Public Access 2022; (1):461-491. doi:10.1146/annurev-bioeng-082420-124920.Modeling
16. Boraschi D, Li D and Li Y: *In-Vitro* and *In-Vivo* Models to Assess the Immune-Related Effects of Nanomaterials. Published online 2021.
17. Leenaars CHC, Kouwenaar C and Stafleu FR: Animal to human translation : a systematic scoping review of reported concordance rates. J Transl Med. Published online 2019; 1-22. doi:10.1186/s12967-019-1976-2
18. Subrizi A, Amo EM, Korzhikov-lakh V, Tennikova T, Ruponen M and Urtti A: Design principles of ocular drug delivery systems : the importance of drug payload, release rate, and material properties. Drug Discov Today. 2019; 24(8): 1446-1457. doi:10.1016/j.drudis.2019.02.001
19. Malek G, Busik J, Grant MB, Choudhary M and Lansing E: discovery. 2019; 13(4): 359-377. doi:10.1080/17460441.2018.1430136.Models
20. Robinson R, Barathi VA, Chaurasia SS, Wong TY and Kern TS: Update on animal models of diabetic retinopathy : from molecular approaches to mice and higher mammals Clinical features of DR. 2012; 456: 444-456. doi:10.1242/dmm.009597

21. Manuscript A: NIH Public Access 2015; 2(2): 47-64. doi:10.5497/wjp.v2.i2.47.Ocular
22. Sher I, Moverman D, Ketter-katz H, Moisseiev E and Rotenstreich Y: *In-vivo* retinal imaging in translational regenerative research 2020; 8(17): 0-3
23. Shah M, Cabrera-ghayouri S, Christie L and Held KS: Translational Preclinical Pharmacologic Disease Models for Ophthalmic Drug Development. Published online 2019.
24. Ointments O: HHS Public Access. Published online 2019; 93-101. doi:10.1016/j.jconrel.2018.03.003.In
25. Leffler CT, Klebanov A, Samara WA and Grzybowski A: The history of cataract surgery : from couching to phacoemulsification 2020; 8(1): doi:10.21037/atm-2019-rcs-04
26. Introduction to electron microscopy of cells. Published online 2001.
27. Ray A, Hadji H, Mitra R, Pal D and Mitra AK: HHS Public Access 2017; 6(6):735-754. doi:10.1007/s13346-016-0339-2.A
28. Boraschi D and Italiani P: Model Validity in Nanoimmunosafety: Advantages and Disadvantages of. Published online 2016; 71-76.
29. Zitter R, Chugh RM and Saha S: Personalized Medicine, and Radiotherapy. Published online 2022.
30. Thoene JG, Delmonte MA and Mullet J: Microvesicle delivery of a lysosomal transport protein to *ex-vivo* rabbit cornea. Mol Genet Metab Reports 2020; 23(2): 100587. doi:10.1016/j.ymgmr.2020.100587
31. Parra-blanco A, Gonzalez N and Arnau MR: *Ex-Vivo* and *In-Vivo* Models for Endoscopic Submucosal Dissection Training. Published online 2012:350-357.
32. Grupcheva CN, Radeva MN, Grupchev DI and Nikolova SP: Contact Lens and Anterior Eye Damage of the ocular surface from indoor suntanning. Insights from *in-vivo* confocal microscopy. Contact Lens Anterior Eye 2021; (3):101438. doi:10.1016/j.clae.2021.03.005
33. Shi D, Mi G, Wang M and Webster TJ: Since January 2020, Elsevier has created a COVID-19 resource center with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource center is hosted on Elsevier Connect, the company s public news and information 2020; (January).
34. Doke SK and Dhawale SC: Alternatives to animal testing: A review. Saudi Pharm J 2015; 23(3): 223-229. doi:10.1016/j.jsps.2013.11.002
35. Craig E, Lowe K and Akerman G: Reducing the need for animal testing while increasing efficiency in a pesticide regulatory setting: Lessons from the EPA Office of Pesticide Programs' Hazard and Science Policy Council. Regul Toxicol Pharmacol 2019; 108(9). doi:10.1016/j.yrtph.2019.104481
36. Toffoletto N, Chauhan A, Alvarez-lorenzo C, Saramago B and Serro AP: Asymmetry in Drug Permeability through the Cornea. Published online 2021.
37. Schaeffer J, Delpech C, Albert F and Belin S: Adult Mouse Retina Explants : From *ex-vivo* to *in-vivo* Model of Central Nervous System Injuries 2020; 13(November):1-19. doi:10.3389/fnmol.2020.599948
38. Horwitz V, Cofen M and Gutman H: Novel Therapeutic Strategies for Sulfur Mustard-Induced Ocular Injury Using the Rabbit Model. Toxicol Lett 2020; 331: 8. doi:10.1016/j.toxlet.2020.05.078
39. Gore A, Lazar S and Yacov G: Ocular surface histopathological insult following sarin and VX exposure and potential treatments in the rat model. Toxicol Lett. 2019; 314(June): 153-163. doi:10.1016/j.toxlet.2019.08.002
40. Lahmar I, Pfaff AW and Marcellin L: Müller cell activation and photoreceptor depletion in a mice model of congenital ocular toxoplasmosis. Exp Parasitol 2014; 144(1): 22-26. doi:10.1016/j.exppara.2014.06.006
41. Ozkan J, Majzoub ME, Coroneo M, Thomas T and Willcox M: Comparative analysis of ocular surface tissue microbiome in human, mouse, rabbit, and guinea pig. Exp Eye Res 2021; 207(4): 108609. doi:10.1016/j.exer.2021.108609
42. Andrade WM, da Silva ACG and Valadares MC: Corneal histomorphometric analysis: The depth of damage induced in the bovine cornea correlates with the severity of the ocular toxicity. Toxicol Vitr 2019; 61(J1): 104593. doi:10.1016/j.tiv.2019.104593
43. Yazdanpanah G, Shah R and Raghurama R Somala S*: In-situ* porcine corneal matrix hydrogel as an ocular surface bandage. Ocu Surf 2021; 21(4): 27-36. doi:10.1016/j.jtos.2021.04.004
44. Pescina S, Santi P and Ferrari G: European Journal of Pharmaceutical Sciences *Ex-vivo* models to evaluate the role of ocular melanin in trans-scleral drug delivery. Eur J Pharm Sci. 2012; 46(5): 475-483. doi:10.1016/j.ejps.2012.03.013


**How to cite this article:**
Shelar S, Mujawar NK and Chakorkar SS: *In-vivo* and *ex-vivo* methods: advancing the frontiers of ocular pharmacological research. Int J Pharm Sci & Res 2024; 15(1): 78-86. doi: 10.13040/IJPSR.0975-8232.15(1).78-86.